Lyngsø Christina, Erikstrup Niels, Hansen Jakob L
Danish National Research Foundation Centre for Cardiac Arrhythmia, Department of Neuroscience and Pharmacology, University of Copenhagen, Copenhagen, Denmark.
Mol Cell Endocrinol. 2009 Apr 29;302(2):203-12. doi: 10.1016/j.mce.2008.09.018. Epub 2008 Sep 27.
The Renin-Angiotensin System (RAS) is important for the regulation of cardiovascular physiology, where it controls blood pressure, and salt- and water homeostasis. Dysregulation of RAS can lead to severe diseases including hypertension, diabetic nephropathy, and cardiac arrhythmia, and -failure. The importance of the RAS is clearly emphasised by the widespread use of drugs targeting this system in clinical practice. These include, renin inhibitors, angiotensin II receptor type I blockers, and inhibitors of the angiotensin converting enzyme. Some of the important effectors within the system are 7 transmembrane (7TM) receptors (or G-protein-coupled receptors) such as the angiotensin II Receptors type I and II (AT1R and AT2R) and the MAS-oncogene receptor. Several findings indicate that the 7TM receptors can form both homo- and heterodimers, or higher orders of oligomers. Furthermore, dimerization may be important for receptor function, and in the development of cardiovascular diseases. This is very significant, since "dimers" may provide pharmacologists with novel targets for improved drug therapy. However, we know that 7TM receptors can mediate signals as monomeric units, and so far it has been very difficult to establish if our observations reflect actual well-defined dimerization or merely reflect close proximity between the receptors and/or various types of functional interaction. In this review, we will present and critically discuss the current data on 7TM receptor dimerization with a clear focus on the RAS, and delineate future challenges within the field.
肾素-血管紧张素系统(RAS)对心血管生理调节至关重要,它控制血压以及盐和水平衡。RAS失调可导致包括高血压、糖尿病肾病和心律失常及心力衰竭在内的严重疾病。临床实践中广泛使用针对该系统的药物,这清楚地强调了RAS的重要性。这些药物包括肾素抑制剂、I型血管紧张素II受体阻滞剂和血管紧张素转换酶抑制剂。该系统内一些重要的效应器是7跨膜(7TM)受体(或G蛋白偶联受体),如I型和II型血管紧张素II受体(AT1R和AT2R)以及MAS癌基因受体。多项研究结果表明,7TM受体可形成同二聚体和异二聚体,或更高阶的寡聚体。此外,二聚化可能对受体功能以及心血管疾病的发展很重要。这非常重要,因为“二聚体”可能为药理学家提供改进药物治疗的新靶点。然而,我们知道7TM受体可作为单体单元介导信号,到目前为止,很难确定我们的观察结果是反映了实际明确的二聚化,还是仅仅反映了受体之间的紧密接近和/或各种类型的功能相互作用。在这篇综述中,我们将展示并批判性地讨论目前关于7TM受体二聚化的数据,明确聚焦于RAS,并阐述该领域未来的挑战。